Clin2
NCT06177925Possibly a fitRecruiting

Immunotherapy plus chemoradiation for limited spread SCLC

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial Neoplasms

Treatments studied

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a combination of an immunotherapy drug (adebrelimab) plus standard chemotherapy and radiation for people with extensive-stage small cell lung cancer that has only spread to a few places. The goal is to see if this approach can help control the cancer better.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
62 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have extensive-stage small cell lung cancer that has spread to a limited number of spots (up to 5 spots in up to 3 organs).
  • You have not had chemotherapy, radiation, or immunotherapy before.
  • You are in good enough health to be up and about (ECOG 0 or 1).
  • You can provide a tumor tissue sample before treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06236997Not yet recruiting· Phase 2
Adebrelimab plus chemoradiation for first-line extensive-stage small cell lung cancer

This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy and radiation to see if it works better than chemotherapy alone for people newly diagnosed with extensive-stage small cell lung cancer.

Zhengzhou, Henan
NCT07103408Not yet recruiting· Phase 2
Chemo-radiation with two immunotherapy drugs for limited-stage small cell lung cancer

This trial combines standard chemotherapy and radiation with two immunotherapy drugs (immune checkpoint inhibitors) to see if they work better together for people with limited-stage small cell lung cancer. It aims to improve outcomes without using strong immune-suppressing medicines.

Guangzhou, Guangdong
NCT06768307Recruiting· Phase 2
Adebrelimab + Chemo with Radiation for Extensive-Stage SCLC

This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.

Beijing, Beijing Municipality
NCT06914050Not yet recruiting· Phase 2
Radiation plus chemotherapy and immunotherapy for limited-stage lung cancer

This trial tests a treatment plan that combines a short course of radiation with chemotherapy and an immunotherapy drug (adebrelimab). It is for people with limited-stage small cell lung cancer who haven't had treatment yet.

NCT06672133Not yet recruiting· Phase 3
Immunotherapy plus chemo and radiation for first-line extensive-stage small cell lung cancer

This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and radiation therapy to see if it works better than standard treatment for people with extensive-stage small cell lung cancer who have not been treated before.

NCT07583550Not yet recruiting· Phase 2
Low-dose radiation plus immunotherapy for lung cancer

This trial tests a low dose of radiation to the chest followed by a combination of an immunotherapy drug (adebrelimab) and chemotherapy for extensive-stage small cell lung cancer. Afterward, you would continue taking adebrelimab alone as maintenance therapy.

Hear when a new Respiratory Tract Neoplasms trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.